Cargando…

Evaluation of MRI in the diagnostic accuracy of extrahepatic metastases in neuroendocrine tumors in comparison with the reference standard somatostatin-receptor–PET/CT

PURPOSE: The aim of this study was to compare the diagnostic performance of different sets of MR sequences in detecting extrahepatic disease of NETs on routine liver magnetic resonance imaging (MRI). METHOD: One hundred twenty-seven patients with NETs with and without hepatic and extrahepatic metast...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ingenerf, Maria, Rübenthaler, Johannes, Wenter, Vera, Zacherl, Mathias, Völter, Friederike, Winkelmann, Michael, Karim, Homeira, Schinner, Regina, Ricke, Jens, Berger, Frank, Schmid-Tannwald, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465364/ https://www.ncbi.nlm.nih.gov/pubmed/37655102 http://dx.doi.org/10.3389/fonc.2023.1194152

Ejemplares similares

Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM
por: Ingenerf, Maria, et al.
Publicado: (2023)

Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study
por: Katharina Ingenerf, Maria, et al.
Publicado: (2021)

(68)Ga-DOTATATE PET/CT and MRI with Diffusion-Weighted Imaging (DWI) in Short- and Long-Term Assessment of Tumor Response of Neuroendocrine Liver Metastases (NELM) Following Transarterial Radioembolization (TARE)
por: Ingenerf, Maria, et al.
Publicado: (2021)

Diagnostic accuracy of SSR-PET/CT compared to histopathology in the identification of liver metastases from well-differentiated neuroendocrine tumors
por: Fabritius, M. P., et al.
Publicado: (2023)

Treatment Assessment of pNET and NELM after Everolimus by Quantitative MRI Parameters
por: Ingenerf, Maria, et al.
Publicado: (2022)

Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [(18)F]SiTATE
por: Eschbach, Ralf S., et al.
Publicado: (2023)

Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs
por: Grawe, Freba, et al.
Publicado: (2023)

Dosimetry and optimal scan time of [(18)F]SiTATE-PET/CT in patients with neuroendocrine tumours
por: Beyer, Leonie, et al.
Publicado: (2021)

Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients
por: Grawe, Freba, et al.
Publicado: (2023)

Distinct mechanisms of hypoglycaemia in patients with somatostatin‐secreting neuroendocrine tumours
por: Wiesli, Peter, et al.
Publicado: (2019)

Primary presentation and clinical course of pediatric and adolescent patients with differentiated thyroid carcinoma after radioiodine therapy
por: Burgard, Caroline, et al.
Publicado: (2023)

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
por: del Olmo-Garcia, Maria Isabel, et al.
Publicado: (2021)

Role of Somatostatin Signalling in Neuroendocrine Tumours
por: Rogoza, Olesja, et al.
Publicado: (2022)

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
por: Klomp, M.J., et al.
Publicado: (2020)

NMR-Based Lipid Metabolite Profiles to Predict Outcomes in Patients Undergoing Interventional Therapy for a Hepatocellular Carcinoma (HCC): A Substudy of the SORAMIC Trial
por: Geyer, Thomas, et al.
Publicado: (2021)

Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms
por: Cantone, Maria Celeste, et al.
Publicado: (2021)

Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors
por: Helgebostad, Rasmus, et al.
Publicado: (2022)

Diagnostic Workup for Patients with Solid Renal Masses: A Cost-Effectiveness Analysis
por: Runtemund, Jasmin, et al.
Publicado: (2022)

Correction to: Injuries of the isolated larynx-hyoid complex in post-mortem computed tomography (PMCT) and post-mortem fine preparation (PMFP) - a comparison of 54 forensic cases
por: Treitl, Karla Maria, et al.
Publicado: (2021)

Injuries of the isolated larynx-hyoid complex in post-mortem computed tomography (PMCT) and post-mortem fine preparation (PMFP) - a comparison of 54 forensic cases
por: Treitl, Karla Maria, et al.
Publicado: (2020)

First-generation somatostatin ligand receptor treatment in a pregnant patient with a neuroendocrine tumor with liver metastases
por: Hummelshøj, Nynne Emilie, et al.
Publicado: (2021)

Somatostatin Receptor 2 Expression Profiles and Their Correlation with the Efficacy of Somatostatin Analogues in Gastrointestinal Neuroendocrine Tumors
por: Watanabe, Hirofumi, et al.
Publicado: (2022)

Response to (225)Ac-PSMA-I&T after failure of long-term (177)Lu-PSMA RLT in mCRPC
por: Ilhan, Harun, et al.
Publicado: (2020)

Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after (177)Lu-PSMA-617 Radioligand Therapy
por: Völter, Friederike, et al.
Publicado: (2021)

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
por: Ambrosini, Valentina, et al.
Publicado: (2022)

Neuroendocrine tumor of the extrahepatic bile duct: A case report
por: Abe, Tsuyoshi, et al.
Publicado: (2017)

Primary extrahepatic biliary neuroendocrine tumor: a case report
por: Taj, Raeda, et al.
Publicado: (2023)

Neuroendocrine Carcinoma of the Extrahepatic Bile Ducts: A Case Report
por: Jevdokimov, Denis, et al.
Publicado: (2023)

Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice
por: Kiesewetter, B., et al.
Publicado: (2022)

Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahepatic Metastases
por: De, Brian, et al.
Publicado: (2023)

Somatostatin Receptor Targeted PET-CT and Its Role in the Management and Theranostics of Gastroenteropancreatic Neuroendocrine Neoplasms
por: Adnan, Aadil, et al.
Publicado: (2023)

Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT
por: Kunz, Wolfgang G., et al.
Publicado: (2018)

Somatostatin Receptor-Based Molecular Imaging and Therapy for Neuroendocrine Tumors
por: Wang, Ling, et al.
Publicado: (2013)

Imaging Somatostatin Receptor Activity in Neuroendocrine-differentiated Prostate Cancer
por: Mori, Hiroshi, et al.
Publicado: (2018)

Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future
por: Stueven, Anna Kathrin, et al.
Publicado: (2019)

Somatostatin receptor scintigraphy in the follow up of neuroendocrine neoplasms of appendix
por: Saponjski, Jelena, et al.
Publicado: (2020)

Clinical usefulness of Somatostatin Receptor Scintigraphy in the Diagnosis of Neuroendocrine Neoplasms
por: Inaba, Yoshitaka, et al.
Publicado: (2022)

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
por: Machado-Alba, J. E., et al.
Publicado: (2022)

Extrahepatic biliary obstrution secondary to neuroendocrine tumor of the common hepatic duct
por: Khan, Faraz A., et al.
Publicado: (2016)

Case of resected small-cell neuroendocrine carcinoma of the extrahepatic bile duct
por: Sugita, Hiroaki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6bd0raq4859vg98pkacou6rj77